Lingyi Zheng

Mr. Lingyi Zheng

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2019 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
MBMatthew Bonaparte
Matthew Bonaparte
LZLingyi Zheng
Lingyi Zheng
SGSanjay Garg
Sanjay Garg
BGBruno Guy
Bruno Guy
YLYaniv Lustig
Yaniv Lustig
YAYasemin Ataman-Önal
Yasemin Ataman-Önal
In September 2018, the World Health Organization recommended that pre-vaccination screening be used with the tetravalent dengue vaccine (CYD-TDV), to ensure that only individuals with evidence of prior dengue infection (PDI) are vaccinated. Dengue rapid diagnostic tests (RDTs) would offer a potential solution for pre-vaccination screening at the point-of-care, but data on performance of available RDTs for identifying PDI are limited. We determined the suitability of four dengue RDTs and two conventional enzyme-linked immunosorbent assays (ELISAs) to identify PDI and evaluated cross-reactivity with co-circulating flaviviruses. Specificity was assessed using 534 dengue negative (determined by 50% plaque reduction neutralization test [PRNT50]) serum samples from USA (n = 229) and dengue-endemic regions (n = 305). Sensitivity was assessed using 270 samples from recent (n = 90) or remote (n = 90) virologically-confirmed prior dengue cases, and dengue PRNT50 positive samples (n = 90). Cross-reactivity was assessed in dengue seronegative samples that were seropositive for yellow fever (n = 57), Japanese encephalitis (n = 37), West Nile (n = 59) or Zika (n = 41). Dengue IgG RDTs and the Panbio ELISA exhibited favourable specificities (99–100%), higher than the Focus ELISA (95%). The RDTs had variable sensitivities (40–70%) that were lower than those of the ELISAs (≥90%). Cross-reactivity to other flaviviruses was low with RDTs (≤7%), but more significant with ELISAs (up to 51% for West-Nile and 34% for Zika). No cross-reactivity to any of the four closely-related flaviviruses was observed with the CTK Biotech RDT. For each serotest, sensitivity appeared similar in samples from individuals with recent (<13 months) versus remote (3–4 years) virologically-confirmed PDI. In general, dengue IgG RDTs were found to be more specific and less cross-reactive than the ELISAs, but the latter were more sensitive for identifying PDI cases. Currently available RDTs could be temporizing tools for rapid and safe pre-vaccination screening until improved RDTs with increased sensitivity become available.

1 November 2019 in Journal of Immunological Methods
Verified
Journal Article
Open access
TTTatyana M. Timiryasova
Tatyana M. Timiryasova
PLPing Luo
Ping Luo
LZLingyi Zheng
Lingyi Zheng
ASAmy Singer
Amy Singer
RZRebecca Zedar
Rebecca Zedar
MBMonique Brown
Monique Brown
The rabies rapid fluorescent focus inhibition test (RFFIT) is the most widely used cell-based assay for detecting and quantitating rabies virus neutralizing antibodies (RVNA) in human serum. However, it is a complex, labor intensive, and somewhat subjective manual assay, the performance of which may be affected by a number of factors including the quality of cells and virus, variability of assay reagents and the skill and expertise of analysts. This study sought to identify and evaluate conditions that may impact RFFIT performance and RVNA detection by evaluating assay parameters including: different serial dilution scheme of serum samples in a 96-well microplate using semi-automated pipetting systems, the range of dose of challenge virus standard (CVS-11) strain of rabies virus, the effect of complement (C'), the effect of cell seeding density and passage number, the effect of diethylaminoethyl (DEAE) dextran concentration on virus infectivity, and the assay incubation period prior to immunostaining. In addition the evaluation of counting fluorescent foci using a microscope versus using scanned images from a cell imaging reader was performed in an effort to ease the reading of slides and have permanent records of the raw data. The results from optimization of each parameter are presented along with subsequent assay validation in accordance with the International Conference on Harmonization (ICH) guidelines. The improved and optimized RFFIT accuracy, linearity and sensitivity was demonstrated by testing World Health Organization (WHO)-1 and WHO-2 Standard Rabies Immune Globulins (SRIGs) and complete assay development and validation was performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines.

3 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CMChong Ma
Chong Ma
JDJiejun Du
Jiejun Du
LLLan Lan
Lan Lan
AKArchana Kapoor
Archana Kapoor
GMGonzalo Perez Marc
Gonzalo Perez Marc
LZLingyi Zheng
Lingyi Zheng
Identifying an immunologic marker as a correlate of protection (CoP) for RSV vaccination is important. In the pivotal phase 3 trial, the mRNA-1345 vaccine demonstrated efficacy against RSV in older adults (NCT05127434). Here, we evaluate neutralizing antibodies (nAb) against RSV-A and -B, and IgG binding antibodies (bAb) to RSV fusion antigens as correlates of risk (CoR) and CoP against the pivotal trial’s efficacy endpoints of RSV lower respiratory tract disease with ≥2 or ≥3 signs/symptoms (RSV-LRTD-2+ and −3 + ) and acute respiratory disease (RSV-ARD). Day 29 RSV nAb and prefusion (preF) IgG demonstrate consistent inverse correlates with RSV endpoint occurrence. Day 29 point estimates (95% CIs) of the hazard ratio of each endpoint (RSV-LRTD-2 + , RSV-LRTD-3 + , RSV-ARD) per 10-fold increase in RSV-A nAb are 0.44 (0.30-0.65), 0.41 (0.20-0.84), and 0.45 (0.28-0.71), respectively, similar to RSV-B nAb and preF IgG. These results demonstrate Day 29 RSV nAb and preF IgG are CoRs and support their role as CoPs against RSV endpoints.

4 September 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
ENEduardo J. M. Nascimento
Eduardo J. M. Nascimento
MBMatthew I. Bonaparte
Matthew I. Bonaparte
PLPing Luo
Ping Luo
TVTimothy S. Vincent
Timothy S. Vincent
BHBranda Hu
Branda Hu
JHJames W. Huleatt
James W. Huleatt
Zika virus (ZIKV) serological diagnostics are compromised in areas where dengue viruses (DENV) co-circulate because of their high levels of protein sequence homology. Here, we describe the characterization of a Zika blockade-of-binding ELISA (Zika BOB) and a Zika microneutralization assay (Zika MN) for the detection of ZIKV nonstructural protein 1 (NS1)–specific antibodies and ZIKV neutralizing antibodies, respectively. Zika BOB and Zika MN cutoffs were established as 10 and 100 endpoint titers, respectively, using samples collected pre- and post-virologically confirmed ZIKV infection from subjects living in DENV-endemic areas. Specificity of the assays was equally high, whereas sensitivity of Zika BOB was lower than that of Zika MN, especially in samples collected > 6 months post-infection. Immunosurveillance analysis, using combined results from both Zika BOB and Zika MN, carried out also in DENV-endemic regions in Colombia, Honduras, Mexico, and Puerto Rico before (2013–2014) and after (2017–2018) ZIKV introduction in the Americas suggests unapparent ZIKV seroprevalence rates ranged from 25% to 80% over the specified period of time in the regions investigated.

1 March 2020 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
MBMatthew Bonaparte
Matthew Bonaparte
JHJames Huleatt
James Huleatt
SHShekema Hodge
Shekema Hodge
LZLingyi Zheng
Lingyi Zheng
YLYaniv Lustig
Yaniv Lustig
SSStephen Savarino
Stephen Savarino
We assessed a dengue IgG rapid diagnostic test (RDT) and IgG enzyme-linked immunosorbent assay (ELISA) to determine their suitability for dengue prevaccination screening. Each exhibited ≥99% specificity. The RDT demonstrated no Zika cross-reactivity, while the ELISA displayed greater sensitivity. Both could safely guide vaccination in Puerto Rico pending availability of improved serotests.

2 December 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
LCLeah Cole
Leah Cole
JZJinrong Zhang
Jinrong Zhang
KPKristl M. Pacheco
Kristl M. Pacheco
PLPhilippe Lhéritier
Philippe Lhéritier
NANatalie G. Anosova
Natalie G. Anosova
NRNathalie Reveneau
Nathalie Reveneau
While both whole-cell (wP) and acellular pertussis (aP) vaccines have been highly effective at reducing the global pertussis disease burden, there are concerns that compared to wP vaccination, the immune responses to aP vaccination may wane more rapidly. To gain insights into the vaccine elicited immune responses, pre-adult baboons were immunized with either aP or wP vaccines, boosted with an aP vaccine, and observed over a nearly two-year period. Priming with a wP vaccine elicited a more Th17-biased response than priming with aP, whereas priming with an aP vaccine led to a more Th2-biased response than priming with wP. These differences were maintained after aP vaccine boost immunizations. Compared to aP, animals primed with a wP vaccine exhibited greater numbers of pertussis specific memory B cells. While aP and wP vaccine priming initially elicited similar levels of anti-pertussis toxin antibody, titers declined more rapidly in aP vaccine primed animals leading to a 4-fold difference. Both wP and aP vaccine immunization could induce serum bactericidal activity (SBA); however, only one wP vaccine immunization was required to elicit SBA while multiple aP vaccine immunizations were required to elicit lower, less durable SBA titers. In conclusion, when compared to aP vaccine, priming with wP vaccine elicits distinct cellular and humoral immune responses that persist after aP vaccine boosting.